Loading...
Imugene Limited
IUGNF•PNK
Healthcare
Biotechnology
$0.26
$-0.00(-1.03%)
Imugene Limited (IUGNF) Financial Performance & Income Statement Overview
Review Imugene Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-8.22%
↓ 8.22%
Operating Income Growth
-174.75%
↓ 174.75%
Net Income Growth
-294.78%
↓ 294.78%
Operating Cash Flow Growth
-241.61%
↓ 241.61%
Operating Margin
-3638.85%
↓ 3638.85%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-3710.44%
↓ 3710.44%
ROE
-95.62%
↓ 95.62%
ROIC
-120.22%
↓ 120.22%
Imugene Limited (IUGNF) Income Statement & Financial Overview
Review Imugene Limited's (IUGNF) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $1.26M | $0.00 | $8.07M | $3.48M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $1.26M | $0.00 | $8.07M | $3.48M |
| Gross Profit Ratio | $1.00 | $0.00 | $1.00 | $1.00 |
| R&D Expenses | $31.30M | $42.21M | $44.68M | $18.21M |
| SG&A Expenses | $19.02M | $25.35M | $34.56M | $11.17M |
| Operating Expenses | $51.09M | $67.56M | $79.23M | $29.39M |
| Total Costs & Expenses | $51.09M | $79.61M | $79.23M | $29.39M |
| Interest Income | $0.00 | $1.95M | $2.56M | $1.40M |
| Interest Expense | $0.00 | $212954.00 | $265407.00 | $0.00 |
| Depreciation & Amortization | $1.31M | -$5.00 | $1.86M | $570352.00 |
| EBITDA | -$48.52M | -$77.31M | -$69.15M | -$10.25M |
| EBITDA Ratio | -$38.57 | $0.00 | -$8.57 | -$2.94 |
| Operating Income | -$49.83M | -$67.56M | -$79.23M | -$29.39M |
| Operating Income Ratio | -$39.61 | $0.00 | -$9.82 | -$8.44 |
| Other Income/Expenses (Net) | $314049.00 | -$9.96M | $2.30M | -$16.65M |
| Income Before Tax | -$49.52M | -$77.52M | -$76.78M | -$27.47M |
| Income Before Tax Ratio | -$39.36 | $0.00 | -$9.52 | -$7.89 |
| Income Tax Expense | -$1.18M | $3.45M | -$8.06M | -$6.95M |
| Net Income | -$48.34M | -$80.97M | -$68.72M | -$20.52M |
| Net Income Ratio | -$38.43 | $0.00 | -$8.52 | -$5.89 |
| EPS | -$0.006 | -$0.01 | -$0.01 | -$0.003 |
| Diluted EPS | -$0.006 | -$0.01 | -$0.01 | -$0.003 |
| Weighted Avg Shares Outstanding | $7.41B | $7.30B | $6.88B | $6.42B |
| Weighted Avg Shares Outstanding (Diluted) | $7.41B | $7.30B | $6.88B | $6.42B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan